Identification of an Abbreviated Test Battery for Detection of HIV-Associated Neurocognitive Impairment in an Early-Managed HIV-Infected Cohort

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Moore, David J ^a   Roediger, Mollie J P ^b,c   Eberly, Lynn E ^b,c   Blackstone, Kaitlin ^a   Hale, Braden ^c,d   Weintrob, Amy ^c,e   Ganesan, Anuradha ^c,e   Agan, Brian K ^c   Letendre, Scott L ^a   Crum Cianflone, Nancy F ^c,d  

^a HIV Neurobehavioral Research Program   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^d NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^e WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; EARLY INTERVENTION; FEMALE; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; SCREENING TEST; SENSITIVITY AND SPECIFICITY;

ADULT; ANTI-RETROVIRAL AGENTS; COGNITION DISORDERS; COHORT STUDIES; HIV; HIV INFECTIONS; HUMANS; NEUROPSYCHOLOGICAL TESTS; PREVALENCE;

EID: 84869066402     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047310     Document Type: Article

References (34)

1. Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, et al. (2010) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 75: 2087-2096.
2. Butters N, Grant I, Haxby J, Judd LL, Martin A, et al. (1990) Assessment of AIDS-related cognitive changes: recommendations of the NIMH Workshop on Neuropsychological Assessment Approaches. J Clin Exp Neuropsychol 12: 963-978.
3. Malloy PF, Cummings JL, Coffey CE, Duffy J, Fink M, et al. (1997) Cognitive screening instruments in neuropsychiatry: a report of the Committee on Research of the American Neuropsychiatric Association. J Neuropsychiatry Clin Neurosci 9: 189-197.
4. Mattis S (1988) Dementia Rating Scale: Odessa, FL.
5. Cherner M, Masliah E, Ellis RJ, Marcotte TD, Moore DJ, et al. (2002) Neurocognitive dysfunction predicts postmortem findings of HIV encephalitis. Neurology 59: 1563-1567.
6. Moore DJ, Masliah E, Rippeth JD, Gonzalez R, Carey C, et al. (2006) Cortical and subcortical neurodegeneration is associated with HIV neurocognitive impairment. AIDS 20: 879-887.
7. Reger M, Welsh R, Razani J, Martin DJ, Boone KB, (2002) A meta-analysis of the neuropsychological sequelae of HIV infection. J Int Neuropsychol Soc 8: 410-424.
8. Power C, Selnes OA, Grim JA, McArthur JC, (1995) HIV Dementia Scale: a rapid screening test. J Acquir Immune Defic Syndr Hum Retrovirol 8: 273-278.
9. McArthur JC, Brew BJ, (2010) HIV-associated neurocognitive disorders: is there a hidden epidemic? AIDS 24: 1367-1370.
10. Carey CL, Woods SP, Rippeth JD, Gonzalez R, Moore DJ, et al. (2004) Initial validation of a screening battery for the detection of HIV-associated cognitive impairment. Clin Neuropsychol 18: 234-248.
11. Smith CA, van Gorp WG, Ryan ER, Ferrando SJ, Rabkin J, (2003) Screening subtle HIV-related cognitive dysfunction: the clinical utility of the HIV dementia scale. J Acquir Immune Defic Syndr 33: 116-118.
12. Richardson MA, Morgan EE, Vielhauer MJ, Cuevas CA, Buondonno LM, et al. (2005) Utility of the HIV dementia scale in assessing risk for significant HIV-related cognitive-motor deficits in a high-risk urban adult sample. AIDS Care 17: 1013-1021.
13. Morgan EE, Woods SP, Scott JC, Childers M, Marquie-Beck J, et al. (2008) Predictive validity of demographically adjusted normative standards for the HIV Dementia Scale. J Clin Exp Neuropsychol 30: 83-90.
14. Jones BN, Teng EL, Folstein MF, Harrison KS, (1993) A new bedside test of cognition for patients with HIV infection. Ann Intern Med 119: 1001-1004.
15. Berghuis JP, Uldall KK, Lalonde B, (1999) Validity of two scales in identifying HIV-associated dementia. J Acquir Immune Defic Syndr 21: 134-140.
16. Cysique LA, Maruff P, Brew BJ, (2004) Antiretroviral therapy in HIV infection: are neurologically active drugs important? Arch Neurol 61: 1699-1704.
17. Sacktor NC, Wong M, Nakasujja N, Skolasky R, Selnes O, et al. (2005) The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS 19: 1367-1374.
18. Marconi VC, Grandits GA, Weintrob AC, Chun H, Landrum ML, et al. (2010) Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History Study. AIDS Res Ther 7: 14.
19. Cherner M, Suarez P, Lazzaretto D, Fortuny LA, Mindt MR, et al. (2007) Demographically corrected norms for the Brief Visuospatial Memory Test-revised and Hopkins Verbal Learning Test-revised in monolingual Spanish speakers from the U.S.-Mexico border region. Arch Clin Neuropsychol 22: 343-353.
20. Heaton RK, Marcotte TD, Mindt MR, Sadek J, Moore DJ, et al. (2004) The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc 10: 317-331.
21. Norman MA, Moore DJ, Taylor M, Franklin D Jr, Cysique L, et al. (2011) Demographically corrected norms for African Americans and Caucasians on the Hopkins Verbal Learning Test-Revised, Brief Visuospatial Memory Test-Revised, Stroop Color and Word Test, and Wisconsin Card Sorting Test 64-Card Version. J Clin Exp Neuropsychol 33: 793-804.
22. Woods SP, Scott JC, Fields JA, Poquette A, Troster AI, (2008) Executive dysfunction and neuropsychiatric symptoms predict lower health status in essential tremor. Cogn Behav Neurol 21: 28-33.
23. Efron BT (1998) An Introduction to the Bootstrap. Boca Raton: Chapman and Hall.
24. SAS [computer program]. Version 9.1. Cary, N.C.
25. Ellis RJ, Evans SR, Clifford DB, Moo LR, McArthur JC, et al. (2005) Clinical validation of the NeuroScreen. J of Neurovirol 11: 503-511.
26. Valcour VG, (2011) Evaluating cognitive impairment in the clinical setting: practical screening and assessment tools. Top Antivir Med 19: 175-180.
27. Gorman AA, Foley JM, Ettenhofer ML, Hinkin CH, van Gorp WG, (2009) Functional consequences of HIV-associated neuropsychological impairment. Neuropsychol Rev 19: 186-203.
28. Ettenhofer ML, Foley J, Castellon SA, Hinkin CH, (2010) Reciprocal prediction of medication adherence and neurocognition in HIV/AIDS. Neurology 74: 1217-1222.
29. Parsons TD, Braaten AJ, Hall CD, Robertson KR, (2006) Better quality of life with neuropsychological improvement on HAART. Health Qual Life Outcomes 4: 11.
30. Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, et al. (2011) HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 17: 3-16.
31. Woods SP, Moore DJ, Weber E, Grant I, (2009) Cognitive neuropsychology of HIV-associated neurocognitive disorders. Neuropsychol Rev 19: 152-168.
32. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, et al. (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69: 1789-1799.
33. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, et al. (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53: 695-699.
34. Achenbach TM, Edelbrock C, Howell CT, (1987) Empirically based assessment of the behavioral/emotional problems of 2- and 3- year-old children. J Abnorm Child Psychol 15: 629-650.